|
To receive daily emails from Breaking Christian News to your inbox CLICK HERE
Drug Developed in Israel Saves 47 of 50 Severe Covid Patients in TrialBonus BioGroup says its MesenCure experimental treatment resulted in 94% survival rate of trial subjects and cut hospitalization time in half.
Study results, soon to be published, show MesenCure treatment reduced study participants' hospitalization period by about half compared to a control group. All these patients had life-threatening pneumonia and respiratory distress caused by Covid-19. The data shows that MesenCure treatment reduced mortality by about 70% compared with the control group. Only two of the first 30 severe Covid-19 patients treated with MesenCure died due to Covid-19 or its complications, while 14 of 60 similar patients in the control group died. MesenCure treatment shortened the hospitalization period of severe Covid-19 patients by eight days on average, a reduction of 45% relative to the control group. The experimental group included women and men aged 41.4 to 77.4. About 77% of the severe Covid-19 patients treated in three hospitals with MesenCure had one or more risk factors for poor prognosis: hypertension, hyperlipidemia, obesity and Type 2 diabetes. Most were treated during the fourth Covid-19 wave in Israel, dominated by the Delta strain. The control group received the current standard of care — anti-inflammatory drugs in combination with steroids. This regimen, according to Bonus BioGroup, reduces mortality in hospitalized Covid-19 patients only slightly, from 25.8% to 21.8%, indicating that MesenCure is four times more effective. "We are proud of our success in leading the world to be a safer place by developing a medication for severe Covid-19 patients, thereby dramatically reducing the threat to their lives," said Dr. Shai Meretzki, CEO of Bonus BioGroup. "In less than two years from the epidemic outbreak, we are the first in the world to report an effective and significant treatment for severely ill patients." According to a statement from Bonus BioGroup, an independent expert committee confirmed the findings of the Phase II clinical trial of MesenCure and recommended continuing toward Phase III. Meretzki told the Jerusalem Post that the company will apply for emergency use approval from European and US regulatory agencies. Subscribe for free to Breaking Christian News here
To receive daily emails from Breaking Christian News to your inbox CLICK HERE
Other Recent Articles from Breaking Christian News America 250: Freedom Trucks Travel across US Celebrating American History Lowest Gas Prices Are in States with Republican Governors, Legislatures: Report MLB's Texas Rangers Shun 'Pride Night,' Host 'Faith and Family Night' Instead Resolution to Preserve Daughters of the American Revolution for Women Only Is Defeated Texas Institutes Bible Passages into Its Public School Reading List Justice Alito Torches SCOTUS Ruling in Mail-in Ballot Case, Warns of Voter Fraud SCOTUS Rules 5-4 to Permit Counting of Mail-In Ballots that Arrive AFTER Election Day America's Semiquincentennial Begins: Trump Launches Massive National Mall Expo Woman Removed from Detroit Tigers Game for Wearing 'Jesus Over Pride' Shirt Netherlands Does the Unthinkable: Euthanize a Young Child European Country Moves to Ban Islamic Call to Prayer (Video) Charlie Kirk Judge Denies Tyler Robinson's Attempt to Have Potential Death Penalty Removed The Reflecting Pool Vandalism Trump Wasn't Supposed to Be Right About Venezuelans Comb Quake Rubble in Search for Survivors: 'There Are Still People Alive in There' Samaritan's Purse Sending Help to Venezuela after Devastating Earthquakes Search the Articles Archives |
All articles on this site and emails from BCN are copyrighted property of Breaking Christian News. Permission is given to link to, or share a BCN story if proper attribution is given to both the original writer and summarizer of the story. Breaking Christian News 2005-2019. All Rights Reserved.
Breaking Christian News is a division of Elijah List Publications, Inc. All Rights Reserved
Disclaimer: Articles and links, as well as the source articles linked to; do not necessarily reflect the opinion of Breaking Christian News.
| Home | Store | Subscribe | Facebook | Article Archive |